|Bid||60.05 x 900|
|Ask||60.28 x 1200|
|Day's Range||58.72 - 60.90|
|52 Week Range||17.51 - 111.36|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||92.78|
Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).
In July, Nektar Therapeutics’ (NKTR) new drug application for NKTR-181 was accepted for filing by the FDA. A first-in-class analgesic, NKTR-181 is targeted at the treatment of chronic low back pain in adult patients who are new to opioid therapy.
How Is Nektar Therapeutics Positioned in August? In February, Nektar Therapeutics (NKTR) and Bristol-Myers Squibb (BMY) entered into a collaboration to jointly develop the former’s NKTR-214 in combination with the latter’s Opdivo and Opdivo plus Yervoy and other compounds. The two companies also agreed that Nektar would retain the right to record all global sales of the drug.
How Is Nektar Therapeutics Positioned in August? Nektar Therapeutics expects an increase in its general and administrative expenses in 2018 compared to 2017 due to higher noncash stock-based compensation expenses. Nektar Therapeutics saw an operating income of -$50.66 million in the second quarter of 2017 compared to its operating income of $973.6 million in the second quarter of 2018.
Nektar Therapeutics (NKTR) generated revenue of $1.09 billion in the second quarter compared to $34.59 million in the second quarter of 2017.
Nektar Therapeutics (NKTR), a research-focused biopharmaceutical company, is developing a strong pipeline of product candidates that make use of its polymer conjugate technology platforms. This pipeline includes investigational drugs for the treatment of cancer, autoimmune disease, and chronic pain.
As the following stock charts of Nektar Therapeutics (NASDAQ:NKTR), Waters (NYSE:WAT) and A.O. Smith (NYSE:AOS) indicate, some stocks are still well-positioned to move higher. Nektar Therapeutics, though, is an exception to that rule of thumb. • A careful look at the daily chart also makes clear that Nektar Therapeutics shares found support at key short-term moving average lines, which is where you’d expect/want to find support.
Nektar's (NKTR) second-quarter earnings meet estimates. Although revenues soar on one-time payment from Bristol-Myers, product sales fall. Shares down.
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / U.S. equities were mixed on Wednesday as a result of disappointing corporate earnings combined with the latest trade news. The Dow Jones Industrial Average ...
Nektar Therapeutics (nktr) shares swung lower in the extended session Wednesday after the biotech company reported quarterly earnings. Nektar shares, which had been up as much as 5% after hours, were last trading down 4.6% in the extended session, following a 2.5% gain to close the regular session at $55.96.
Nektar (NKTR) delivered earnings and revenue surprises of 0.00% and 4.32%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
The San Francisco-based company said it had net income of $5.33 per share. The results met Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was also ...
SAN FRANCISCO , Aug. 8, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) today reported its financial results for the second quarter ended June 30, 2018 . Cash and investments in marketable securities ...
NEW YORK, NY / ACCESSWIRE / August 8, 2018 / Nektar Therapeutics (NASDAQ: NKTR ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 8, 2018 at 5:00 PM Eastern Time. ...
Nektar Therapeutics (NKTR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP.
Bristol-Myers Squibb’s (BMY) geographic segments are classified into the US, Europe, Rest of World, and Other categories. In the next article, we’ll take a look at Bristol-Myers Squibb’s collaborations with Biogen and Roche Holding and the recent major approvals of the company’s products.
Bristol-Myers Squibb (BMY) generated total revenue of $5.70 billion in the second quarter compared to $5.14 billion in the second quarter of 2017. Bristol-Myers Squibb’s product sales, which contribute the bulk of its revenue, increased from $4.77 billion in the second quarter of 2017 to $5.46 billion in the second quarter of 2018. For 2018 and 2019, Bristol-Myers Squibb is expected to generate revenues of $22.26 billion and $23.45 billion, respectively.
Nektar Therapeutics (NKTR) is likely to beat estimates when it reports second-quarter results. Investors are expected to focus on pipeline progress.
In studies, Nektar found opioid abusers rated its experimental, pain-killing opioid, which takes longer to reach the brain, as less likable than oxycodone.
SAN FRANCISCO , Aug. 1, 2018 /PRNewswire/ -- Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter on Wednesday, August 8, 2018, after the close of U.S.-based financial ...
Square Inc. now controls nearly half a million square feet in San Francisco after adding more than 100,000 square feet.
Today, the FDA approved United Therapeutics’ (UTHR) new drug application for its Implantable System for Remodulin (or ISR).
SAN FRANCISCO, July 30, 2018 /PRNewswire/ -- Nektar Therapeutics (NKTR) today announced that the U.S. Food and Drug Administration (FDA) has filed and accepted for review the company's New Drug Application (NDA) for NKTR-181 for the treatment of chronic low back pain in adult patients new to opioid therapy. Nektar's NDA submission is supported by an extensive clinical and nonclinical data package.